Abstract:Pheochromocytoma and paraganglioma (PPGL) are rare tumors derived from the adrenal medulla and extra-adrenal chromaffin cells. Diagnosis is often challenging due to the great variability in clinical presentation; the complexity of management due to the dangerous effects of catecholamine excess and the potentially malignant behavior require in-depth knowledge of the pathology and multidisciplinary management. Nowadays, diagnostic ability has certainly improved and guidelines and consensus documents for treatment and follow-up are available. A major impulse to the development of this knowledge has come from the new findings on the genetic and molecular characteristics of PPGLs. Germline mutation in susceptibility genes is detected in 40% of subjects, with a mutation frequency of 10–12% also in patients with sporadic presentation and genetic testing should be incorporated within clinical care. PPGL susceptibility genes include "old genes" associated with Neurofibromatosis type 1 (NF1 gene), Von Hippel Lindau syndrome (VHL gene) and Multiple Endocrine Neoplasia type 2 syndrome (RET gene), the family of SDHx genes (SDHA, SDHB, SDHC, SDHD, SDHAF2), and genes less frequently involved such as TMEM, MAX, and FH. Each gene has a different risk of relapse, malignancy, and other organ involvement; for mutation carriers, affected or asymptomatic, it is possible to define a tailored long-life surveillance program according to the gene involved. In addition, molecular characterization of the tumor has allowed the identification of somatic mutations in other driver genes, bringing to 70% the PPGLs for which we know the mechanisms of tumorigenesis. This has expanded the catalog of tumor driver genes, which are identifiable in up to 70% of patients Integrated genomic and transcriptomic data over the last 10 years have revealed three distinct major molecular signatures, triggered by pathogenic variants in susceptibility genes and characterized by the activation of a specific oncogenic signaling: the pseudo hypoxic, the kinase, and the Wnt signaling pathways. These molecular clusters show a different biochemical phenotype and clinical behavior; they may also represent the prerequisite for implementing customized therapy and follow-up.

A Signal-to-Cutoff Ratio in the Abbott Architect HIV Ag/Ab Combo Assay That Predicts Subsequent Confirmation of HIV-1 Infection in a Low-Prevalence Setting

The Molecular Classification of Pheochromocytomas and Paragangliomas: Discovering the Genomic and Immune Landscape of Metastatic Disease

Chromatin changes in frog neurons after eighth nerve transection.

Genetics and imaging of pheochromocytomas and paragangliomas: current update

A QoS provisioning framework for high-speed multimedia wireless networks

Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies

Pheochromocytoma and Paraganglioma: A Review of Diagnosis, Management and Treatment of Rare Causes of Hypertension

Adrenocortical carcinoma presenting as a rupture and extensive retroperitoneal haemorrhage.

Pheochromocytoma–Paraganglioma Syndrome: A Multiform Disease with Different Genotype and Phenotype Features

The adrenal medulla and extra-adrenal paraganglia: then and now

Metastatic Pheochromocytomas and Abdominal Paragangliomas

The Management of Phaeochromocytomas and Paragangliomas in the Era of Precision Medicine: Where Are We Now? Evidence-Based Systemic Treatment Options and Future Cluster Oriented Perspectives

The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives

Enteroviruses in the environment.

Update on clinical characteristics in the evaluation of phaeochromocytoma and paraganglioma

Personalized oncology in pheochromocytomas and paragangliomas: integrating genetic analysis with machine learning

Metastatic Pheochromocytoma and Paraganglioma: Focus on Therapeutics

Multidisciplinary graduate training for biomedical science.

Management of Pheochromocytomas and Paragangliomas

Novel Gene Variants in a Nationwide Cohort of Patients with Pheochromocytoma and Paraganglioma

Imaging of Pheochromocytomas and Paragangliomas